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Abstract: Chronic hand eczema is a debilitating dermatological condition with significant 
  economic, social, and functional impacts. To date, conventional treatments such as topical 
  corticosteroids, phototherapy, and systemic immunosuppressants have yielded disappointing 
results, owing to either a lack of efficacy or significant adverse events. Oral alitretinoin 
(9-cis-retinoic acid) is a unique panagonist retinoid with immunomodulatory and anti-
  inflammatory activity that has emerged as a novel treatment for chronic hand eczema. Several 
large-scale clinical studies have demonstrated oral alitretinoin’s high efficacy rate of 28% to 89%, 
its safe tolerability profile, and its positive impact on quality of life, validating it as a therapeutic 
option for patients with severe chronic hand eczema refractory to standard treatment.
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Chronic hand eczema
Background
Eczema is the most common dermatological disorder of the hands, with an annual prev-
alence of up to 12% and 16% in parts of Europe and the United States, respectively.1,2 
Hand eczema is characterized by vesicles, papules, erythema, edema, scaling, fissures, 
and hyperkeratosis, as well as pruritic and painful symptoms.3,4 While there is no 
specific morphological classification system, clinical subtypes include vesicular, 
atopic, endogenous, discoid, acral, irritant, pompholyx, and hyperkeratotic eczema.5 
Included in the differential diagnosis are irritant contact dermatitis, allergic contact 
dermatitis, endogenous eczema, psoriasis/pustulosis, fungal infection, keratoderma, 
lichen planus, and granuloma annulare.6
Hand eczema has a multi-factorial etiology, involving both endogenous and 
exogenous factors.7 The primary endogenous predisposing factor is a history of atopy, 
which is the underlying etiology in as high as 50% of affected individuals.3 Genetic 
inheritance also plays a role, as demonstrated by a recent population-based twin cohort 
study.8 Exogenous factors primarily include exposure to irritants (ie, food, oils, soap, 
solvents), and contact allergens (ie, nickel, chromate, rubber). Occupational exposure 
to these causative agents, primarily among dressers, cooks, healthcare workers, for 
example, are the most common causes of hand eczema.9 The interrelatedness of these 
etiologies renders it difficult to isolate and remove the offending agents, and is therefore 
a factor for development of hand eczema into a chronic, relapsing course.
When hand eczema persists for more than 6 months despite therapeutic measures, 
it is considered to be a chronic form.6 This variant of hand eczema develops in Clinical, Cosmetic and Investigational Dermatology 2010:3 60
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5% to 7% of affected individuals and has significant social, 
psychological, occupational, and economic impacts.10,11 Not 
only does this painful condition affect the utility of the hands 
in performing mechanical work, but the often disfiguring 
manifestations lead to negative social stigmata.3 A recent 
cross-sectional, multi-center study of 416 patients demon-
strated that affected individuals had a significantly decreased 
quality of life, which was directly correlated to the severity 
of their disease.12
Management
A broad variety of both pharmacological and non-
  pharmacological strategies exist for the management of 
chronic hand eczema. These are usually delivered in a 
step-wise approach and begin by lifestyle modifications, 
including educating the patient about the avoidance of irri-
tants and allergens, the avoidance of occupational-related 
irritation, and the use of emollients.6 A recent clinical study 
demonstrated that petroleum-based emollients and skin 
lipid-based emollients are equally effective therapeutic 
measurements for hand eczema, and patients should be 
encouraged to use them as an adjunct to other therapies.13 
Topical steroids are usually the first-line pharmacological 
measure, but their use is limited by the adverse effects of 
skin atrophy, tachyphylaxis, potential adrenal suppression, 
and their futility in treating severe manifestations.14,15 
  Phototherapy with UVA-1 and UVB has been successfully 
used in the treatment of chronic hand eczema, but the 
inadequacy of evidence-based trials has limited its use.16,17 
Systemic oral immunosuppressants, such as azathioprine, 
ciclosporin, and mycophenolate mofetil, have also been 
used with various responses. However, most of these are not 
licensed for the treatment of chronic hand eczema, owing to 
the lack of clinical evidence supporting their lack of efficacy 
and safety. Oral corticosteroids are also an option, but their 
long-term use is limited by well-studied adverse affects 
such as osteoporosis, hyperglycemia, cataracts, hyperten-
sion, and immunosuppression.18 A recent epidemiological 
study reviewing various clinical trials from 1977 to 2003, 
which mostly involved the use of the above-mentioned 
topical steroids, systemic immunosuppressants, and UV 
irradiation, concluded that the poor quality of the studies 
was not sufficient to dictate clinical management of chronic 
hand eczema.19
The high prevalence of chronic hand eczema, its adverse 
impact on quality of life, and its failure to respond to standard 
therapeutic measures has ignited much recent interest in the 
search for an effective and tolerable medication.
Alitretinoin
Background
Oral alitretinoin (9-cis-retinoic acid; Toctino®; Basilea 
Pharmaceuticals, Ltd., United Kingdom), an endogenous 
retinoid, is the only drug that has been specifically 
approved as a treatment option for adults with chronic hand 
eczema unresponsive to topical steroids.6 Retinoids are 
naturally occurring and synthetic derivatives of vitamin A, 
which plays an important role in the immune system by 
  enhancing cytotoxicity, T-cell proliferation, and, under 
some conditions, B-cell proliferation.20 Concurrently, 
retinoids are also involved in fetal development, bone 
formation, cell proliferation, cell differentiation, apoptosis, 
hematopoiesis, and vision.21 These influences are mediated 
through the binding and subsequent activation of two types 
of intracellular receptors: retinoic acid receptors (RARs) 
and retinoid X receptors (RXRs), which each contain three 
different subgroups, α, β, and γ.22,23 While other retinoids 
are limited in their binding to subgroups of either RARs 
or RXRs, alitretinoin is a unique panagonist that binds to 
all six retinoid receptors with high affinity, with a greater 
affinity for RARs than for RXRs.24
Given its effects on cell proliferation, alitretinoin is 
a potent teratogen and is therefore contraindicated in 
pregnant women and women who might become pregnant 
during the course of treatment.25 Moreover, studies on rat 
embryos have demonstrated that it can cause deleterious 
malformations at the second visceral arch.26 Alitretinoin’s 
effects on cell proliferation have been exploited for benefi-
cial effects as well; a recent study demonstrated its ability 
to induce apoptosis in breast cancer cells.27 In addition to 
exerting its effects on cell proliferation, alitretinoin has also 
been shown to produce an anti-inflammatory response by 
inhibiting the production of nitric oxide and such proin-
flammatory molecules as tumor necrosis factor (TNF)-α, 
interleukin (IL)-1 β, and IL-12 p40.28 Since eczema is 
mediated through the Th1 cellular immune response, the 
inhibition of these cytokines by alitretinoin could explain 
its therapeutic efficacy. The immunological manipulation 
by oral alitretinoin was also the basis for two phase II 
trials in the treatment of AIDS-related Kaposi’s sarcoma, 
a cutaneous tumor mediated by HHV-8. 60 and 57 partici-
pants received treatment for a median of 15 weeks, with 
an overall response rate of 37% and 39%, respectively. 
Yet despite its efficacy, the investigators concluded that 
serious adverse events at high doses, such as pancreatitis 
and hypercalcinuria, limit its potential use for the treatment 
of Kaposi’s sarcoma.29,30Clinical, Cosmetic and Investigational Dermatology 2010:3 61
Alitretinoin in treatment of chronic hand eczema Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
The metabolic effects of alitretinoin have also been exten-
sively studied. It was recently shown to increase sex steroid 
synthesis in the rat hippocampus and therefore play a role in 
reproductive behavior.31 It was also shown to have protective 
effects against ischemia-induced brain injury in rats, with 
implications for its use in patients susceptible to strokes.32
Oral alitretinoin has only been clinically approved for its use 
in chronic hand eczema, but recent studies have demonstrated 
its potential use in other dermatologic settings. In a small study 
with six patients who were treated for the hand eczema, alitreti-
noin was also shown to be effective in treating lesions of their 
extrapalmar atopic eczema.33 Furthermore, a recent case report 
of two patients treated with alitretinoin for palmoplantar hyper-
keratotic-rhagadiform had a surprising clinical improvement 
of their Sezary syndrome and mycosis fungoides, implicating 
its potential use for cutaneous T-cell lymphomas.34
While alitretinoin potentially has profound dermatologi-
cal and non-dermatological applications, this review focuses 
on its treatment for chronic hand eczema.
Clinical studies (Table 1)
In a pilot open-label study in 1999, thirty-eight patients 
(19 men and 19 women) with chronic hand eczema unre-
sponsive to conventional treatment were treated with 
20–40 mg of oral alitretinoin for 1 to 5 months.25 The various 
classifications of their hand eczema included hyperkeratotic 
palmar eczema, fingertip eczema, pompholyx, and discoid 
eczema. Lesions and symptoms consisting of erythema, 
vesicles/papules, desquamation, hyperkeratosis, rhagades, 
and pruritis/pain, were objectively recorded by the physi-
cians on a 4 point scale (0 = none, 1 = slight, 2 = moderate, 
3 = marked, 4 = severe), and the reduction of their total 
score was expressed in a percentage. The patients assessed 
their own responses subjectively using the same 4 point 
scale. Side effects, such as headache, chelitis, conjunctivitis, 
and other mucocutaneous manifestations, were similarly 
recorded on a 4 point scale. Objective assessment by the phy-
sicians determined that 55% of the patients showed a “very 
good” response, 34% showed a “good response,” 2 patients 
showed a “moderate” response, and 2 patients did not show 
any response. The mean reduction of the total lesions and 
symptoms was 86% in the 36 patients who responded to 
treatment, with all various forms responding in a similar 
manner. Subjective assessment by the patients yielded 
similar results, as 66% believed they showed a “very good” 
response, 26% believed they showed a “good” response, 
1 felt a “moderate” response, and 2 did not believe they 
responded to the treatment. 7 patients experienced a recur-
rence of their lesions after discontinuation of the therapy, 
but a second regimen of treatment resulted in a successful 
response similar to the first course, thereby demonstrating a 
lack of resistance to the medication. Only mild side effects 
related to hypervitaminosis A were noted, namely transient 
headache, chelitis, transient flushing, and conjunctivitis. 
Overall, the pilot study demonstrated the efficacy of alitreti-
noin, as 89% of the patients assessed by the physician and 
92% assessed by the patients showed a positive therapeutic 
response with minimal side effects.
Table 1 Summarized results of clinical trials of oral alitretinoin in the treatment of refractory chronic hand eczema
Investigators  Date of study  Patients  Type of study  Alitretinoin doses  Duration of  
treatment
Responders 
Bollag and Ott24 1999 38 patients Exploratory  
open-label
20 mg, 40 mg once 
daily
1–5   months 
(mean 
2.3 months)
89% assessed as “very 
good” or “good” 
response by physician
Ruzicka et al34 2004 348 Randomized, 
double-blind, 
placebo-control, 
prospective trial
placebo, 10 mg, 
20 mg, 40 mg once 
daily
12 weeks PGA: 39%, 41%, 53%; 
PaGA: 29%, 34%, 43%; 
TLSS: -59%, -52%, 
-70.5% (10 mg, 20 mg, 
40 mg)
Ruzicka et al35 2008 1032 Randomized, 
double-blind, 
placebo-control, 
prospective trial
placebo, 10 mg, 
30 mg once daily
12–24 weeks PGA: 28%, 48%,; PaGA: 
24%, 40%; mTLSS: -56%, 
-75%, (10 mg, 30 mg)
Bissonnette et al37 
 
 
2009 
 
 
117 (patients 
who relapsed 
from 2008 trial) 
Randomized, 
double-blind, 
placebo-control, 
prospective trial
placebo, 10 mg, 
30 mg once daily 
 
12–24 weeks 
 
 
PGA: 48%, 80%; PaGA: 
38%, 76%; mTLSS: 71%, 
92% (10 mg, 30 mg) 
Abbreviations: PGA, physician’s global assessment; PaGA, patient’s global assessment; TLSS, total lesion symptom score.Clinical, Cosmetic and Investigational Dermatology 2010:3 62
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In a larger randomized, double-blind, placebo-control 
study in 2004, alitretinoin was again determined to be an 
efficacious and well-tolerated treatment for the treatment 
of refractory chronic hand eczema.35 The study was held in 
43 clinics across Europe, enrolling 319 patients with moder-
ate or severe refractory chronic hand eczema. Patients were 
randomized into four treatment groups of placebo, 10 mg, 
20 mg, and 40 mg of oral alitretinoin taken once a day for 
12 weeks, and assessed at the end of the study as well as 
at a 3 month follow-up. The primary efficacy measure for 
the therapeutic response used by the researchers were the 
physician’s global assessment (PGA) of overall severity, 
which was categorized into “clear,” “almost clear,” “mild,” 
“moderate,” and “severe.” Patients were considered to be 
responders if they were rated as “clear” (no residual visible 
dermatitis) or “almost clear” (minimal erythema and/or 
scaling) at the end of the 12-week study. The total lesion 
symptom score (TLSS), the patient’s global assessment 
(PaGA) of improvement, and the extent of disease were used 
as secondary efficacy measures. At the end of the study, the 
PGA assessment yielded results of 27%, 39%, 41%, and 
53% responders to placebo, 10 mg, 20 mg, and 40 mg doses, 
respectively. The researchers suggested that the response rate 
in the placebo group may be related to a variety of factors 
such as the natural course of the disease, placebo effects, 
or changes in influential factors of the disease (eg, climate, 
level of stress, occupation). The Cochran–Armitage trend 
test demonstrated a significant dose-dependent effect 
(P  0.001). The PaGA assessment yielded similar results of 
12%, 29%, 34%, and 43% responders to the placebo, 10 mg, 
20 mg, and 40 mg doses, respectively, which was shown 
to be significant by χ2 test (P = 0.01 for 10 mg, P = 0.002 
for 20 mg, and P  0.001 for 40 mg). For all dosages of 
alitretinoin, the median TLSS was higher compared to 
placebo (decreases of 25%, 59%, 52%, and 70.5% for the 
placebo, 10 mg, 20 mg, and 40 mg doses, respectively). 
These results were shown to be significant (P  0.001) 
with the Kruskal–Wallis test, and showed dose-dependence 
(P  0.001) with the Jonckheere–Terpstra trend test). Safety 
evaluation of the drug at a 4 week follow-up revealed adverse 
effects only in the 40 mg dosage group, which included 
headache, flushing, hyperlipidemia, decreased hemoglobin 
level, and decreased free thyroxin level. Three months after 
cessation of treatment, it was revealed that 26% of patients 
relapsed in a dose-independent manner. Overall, this study 
demonstrated that alitretinoin at well-tolerated doses effec-
tively resulted in positive responses in up to 53% of patients 
and up to a 70% mean reduction in signs and symptoms.
In 2008, the results of a large, randomized, double-blind, 
placebo-controlled, parallel-group phase III study, the 
  Benefit of Alitretinoin in Chronic Hand Dermatitis 
(BACH), were published.36 The study was conducted in 
111 clinics throughout Europe and Canada, enrolling 
1032 patients with severe refractory chronic hand eczema. 
The patients were randomized to three treatment groups of 
placebo (n = 205), 10 mg (n = 418), or 30 mg (n = 409) of 
oral alitretinoin administered once daily for up to 24 weeks. 
Patients stopped treatment if they responded within the first 
12 weeks, while the others continued for the full duration 
of the study. The types of chronic hand eczema included 
hyperkeratotic, pompholyx, fingertip, and other, which was 
seen in 85%, 27%, 46%, and 14% of patients, respectively. 
As with the previous study, the investigators used PGA 
as the primary efficacy parameter, whereby patients were 
considered to be responders if they were rated as “clear” or 
“almost clear.” Secondary endpoints used were PaGA and 
a modified TLSS (mTLSS). The results of the investigation 
were concordant with the results in the previous study in 
2004. The PGA results demonstrated a dose-dependent 
efficacy with 48%, 28%, and 17% responders in the 30 mg, 
10 mg, and placebo group, respectively. These results were 
confirmed by the secondary endpoints; the percentage of 
patients with clearing as determined by the PaGA were 
40%, 24%, and 15%, and the median percentage reductions 
in mTLSS were 75%, 56%, and 39% in the 30 mg, 10 mg, 
and placebo groups respectively. There was not a uniform 
response rate amongst the various morphological classifi-
cations of hand eczema. For instance, in the 30 mg treat-
ment group, there was a 49% response rate in those with 
hyperkeratotic features and a 33% response rate in those 
with the pompholyx variant. However, these classifications 
were not mutually exclusive so it would not be feasible to 
conclude that alitretinoin is more effective in one variant 
over the other. There was also a dose-dependence seen 
with the time to response, as it was significantly shorter in 
the 30 mg group than the 10 mg group (P  0.001). The 
median time to relapse, which the investigators defined 
as a recurrence of 75% of the initial signs and symp-
toms in the absence of treatment, was 5.5 to 6.2 months. 
Adverse events were seen in 49.5%, 37.1%, and 34.5% of 
the respective treatment groups, of which headache was 
the most commonly reported. Serious adverse events were 
minimal, with only 1% of patients in each treatment group 
reporting such a problem. One fatal event was reported 
in the 10 mg group, although it was from a myocardial 
infarction unrelated to treatment. Typical retinoid-related Clinical, Cosmetic and Investigational Dermatology 2010:3 63
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laboratory abnormalities were noted, which included 
increases in serum cholesterol and triglyceride levels, and 
decreases in thyroid-stimulating hormone (TSH). As the 
largest clinical investigation on chronic hand eczema to 
date, this study demonstrated promising results of dose-
dependent efficacy of oral alitretinoin that were consistent 
with previous studies.
In 2009, the results of an extension of the BACH study 
were published.37 This investigation examined the efficacy 
and safety of oral alitretinoin in patients who initially 
responded well to treatment in the BACH study, but had 
relapsed within 24 weeks. 117 patients were randomized to 
three treatment groups; placebo (n = 47), 10 mg (n = 21), 
and 30 mg (n = 49). Of the 31 previous responders to 10 mg 
of alitretinoin, 10 received placebo and 21 received alitreti-
noin 10 mg/day. Of the 73 previous responders to 30 mg of 
alitretinoin, 24 received placebo and 49 received alitretinoin 
30 mg/day. The remaining participants in the study were 
13 responders to previous treatment with placebo. Patients 
were treated for 24 weeks, but they stopped treatment if 
they responded within the first 12 weeks. Consistent with 
the previous large scale studies, the investigators used PGA 
as the primary efficacy parameter, and the PaGA and a 
mTLSS as the secondary parameters. Response rates were 
80% (n = 39) in patients retreated with 30 mg of alitretinoin, 
compared to 8% (n = 2) for patients retreated with placebo. 
Response rates were 48% (n = 10) in patients retreated 
with 10 mg of alitretinoin, compared to 10% (n = 1) for 
placebo. The secondary endpoints correlated with the PGA 
results; the median percentage reduction in mTLSS was 
92% for the 30 mg group and 71% for the 10 mg group, 
while the PaGA results demonstrated that 76% (n = 37) of 
patients in the 30 mg group and 38% (n = 8) of patients in 
the 10 mg group reported “clear” or “almost clear” hands. 
Adverse events were similar in frequency to the previous 
studies, with headache being the most common. Six patients 
in total (2 from each treatment group) withdrew from the 
study due to adverse events. Laboratory abnormalities were 
comparable to those reported in previous studies, namely 
hypercholesterolemia, increased triglyceride levels, and 
reduced TSH levels. This investigation was the first to 
show the long-term management of chronic hand eczema 
with intermittent systemic treatment, as it demonstrated the 
efficacy of retreatment with oral alitretinoin in patients who 
had previously relapsed.
Chronic hand eczema has a significant detrimental effect 
on quality of life, work productivity, activity impairment, 
and heath care costs.38 While previous investigations have 
demonstrated the clinical efficacy and tolerability of oral 
alitretinoin, there have been little to no data regarding its 
impact on the patient’s quality of life. Blome et al recently 
presented a method whereby patients answered two sets of 
questionnaires to weigh the importance of their treatment 
needs (Patient Needs Questionnaire) against their achieved 
benefits (Patient Benefit Questionnaire).39 Patient’s needs 
and achieved benefits included “to be pain free,” “have lower 
personal treatment costs,” and to “be able to touch others.” 
The resultant Patient Benefit Index (PBI) was calculated 
from the importance of needs before therapy and the achieve-
ment of these needs. The instrument was utilized in an open 
label study in the safety and efficacy of oral alitretinoin in 
249 patients with severe refractory hand eczema, in which 
the patients received 24 weeks of treatment with 30 mg of 
oral alitretinoin daily. Based on the PBI, an overwhelming 
84.3% of the patients had achieved at least minimal benefit 
from alitretinoin, and 14.1% of patients had their treatment 
needs completely fulfilled. The most common needs the 
patients wanted were to have their skin lesions improved, 
have confidence in therapy, get rid of itching, and to find 
a clear diagnosis and therapy. Likewise, the most common 
treatment benefits included having confidence in the therapy, 
having confidence in the therapy, and being free of itching, 
as well as to lead a normal daily life. Overall, all treatment 
needs after alitretinoin therapy had been achieved by at least 
57% of the patients.
Conclusion
Chronic hand eczema is a debilitating disease with profound 
social, functional, psychological, and economical impacts. 
Standard management to date has failed to provide an effi-
cacious and convenient form of therapy without dangerous 
adverse reactions. In view of several controlled clinical stud-
ies, oral alitretinoin has been proven to be an effective and 
safe treatment modality in refractory patients with a high 
disease burden. The current approved drug dosing is 30 mg 
daily for 12 to 24 weeks, depending on the response, with a 
dose decrease to 10 mg if any serious adverse reactions are 
experienced.40 This is conceivably the most appropriate pro-
tocol, based on results of the clinical trials that demonstrated 
dose-dependent responses and minimal side effects. A recent 
appraisal by the National Institute for Health and Clinical 
Excellence (NICE) supported this protocol and made recom-
mendations as to when treatment should be stopped. They 
advocated that the prescribing physician stop treatment once 
the patient has an adequate response, if the degree of hand 
eczema continued to be severe after 12 weeks of treatment, Clinical, Cosmetic and Investigational Dermatology 2010:3 64
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or if there was an inadequate response at 24 weeks.41 In the 
scenario where the patient relapses after having demonstrated 
an adequate response, re-administration of the drug would 
be a suitable option.
Oral alitretinoin has recently been approved in several 
European countries, but despite positive results, it still 
faces several challenges for US approval. This impedance 
can be attributed to revolving teratogenic concerns, its 
dose-dependent side effects, and a lack of long-term data 
on its effects on bone density. Furthermore, the pharmaco-
economics of the drug must be further explored prior to US 
approval.24 Lastly, adjunct therapies with alitretinoin must be 
further explored, as studies investigating these are lacking. 
Nonetheless, oral alitretinoin has emerged as a promising 
treatment for patients with chronic hand eczema refractory 
to conventional medications.
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